Skip to content
Advertisement

FILE - In this Monday, March 1, 2021, file photo, a woman receives the AstraZeneca COVID-19 vaccine, manufactured by the Serum Institute of India, in Noida, a suburb of New Delhi, India. The world's largest vaccine maker, based in India, will be able to restart exports of AstraZeneca doses by June if new coronavirus infections subside in the country, its chief executive said Tuesday, April 6. But a continued surge could result in more delays because the Serum Institute of India would have to meet domestic needs, Adar Poonawalla warned in an interview with The Associated Press. (AP Photo/Altaf Qadri)

FILE - In this Monday, March 1, 2021, file photo, a woman receives the AstraZeneca COVID-19 vaccine, manufactured by the Serum Institute of India, in Noida, a suburb of New Delhi, India. The world's largest vaccine maker, based in India, will be able to restart exports of AstraZeneca doses by June if new coronavirus infections subside in the country, its chief executive said Tuesday, April 6. But a continued surge could result in more delays because the Serum Institute of India would have to meet domestic needs, Adar Poonawalla warned in an interview with The Associated Press. (AP Photo/Altaf Qadri)

Featured Photo Galleries